Stockreport

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF Product Revenue: Up 434% in Q3 2025 versus Q3 2024, with year-to-date sales of $74.7 million. ANKTIVA ® Unit Growth: 467% unit sales volume growth in year-to-date 202 [Read more]